Quantification of antiretroviral drugs for HIV-1 in the male genital tract: Current data, limitations and implications for laboratory analysis

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 11, 2007, Pages 1451-1462

  Chan, Derek J ^a,c   Ray, John E ^b  

^a Sexual Health Service   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Albion Street Centre ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

DRUG PENETRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LOW DRUG DOSE; MALE GENITAL SYSTEM; MORBIDITY; MORTALITY; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SEMEN ANALYSIS; SEXUAL TRANSMISSION;

ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; DIFFUSION; GENITALIA, MALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PERMEABILITY; REPRODUCIBILITY OF RESULTS; SEMEN;

EID: 35848942346     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.11.0001     Document Type: Review

References (94)

1. Aarnoutse, R. E., Verweij-van Wissen, C. P., van Ewijk-Beneken Kolmer, E. W., Wuis, E. W., Koopmans, P. P., Hekster, Y. A., Burger, D. M. (2002) International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents. Chemother. 46: 884-886
2. Anderson, P. L., Noormohamed, S. E., Henry, K., Brundage, R. C., Balfour, H. H. Jr, Fletcher, C. V. (2000) Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy 20: 917-922
3. Ball, J. K., Rowe, T., Curran, R., Irving, W. L., Beards, G. M., Sontag, G., Youle, M., Moyle, G., Pillay, D. (1999) Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. Sex. Transm. Infect. 75: 337-339
4. Barbour, J. D., Hecht, F. M., Wrin, T., Liegler, T. J., Ramstead, C. A., Busch, M. P., Segal, M. R., Petropoulos, C. J., Grant, R. M. (2004) Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18: 1683-1689
5. Barroso, P. F., Schechter, M., Gupta, P., Melo, M. F., Vieira, M., Murta, F. C., Souza, Y., Harrison, L. H. (2000) Effect of antiretroviral therapy on HIV shedding in semen. Ann. Intern. Med. 133: 280-284
6. Bartlett, J. G., Gallant, J. E. (2004) Antiretroviral therapy. In: Medical management of HIV infection, 2004 edn. John Hopkins Medicine Publishing Business Group, Maryland
7. Blower, S. M., Gershengorn, H. B., Grant, R. M. (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650-654
8. Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Mulder, J. W., Meenhorst, P. L., Koopmans, P. P., Brinkman, K., Keuter, M., Dolmans, W., Hekster, Y. A. (1998) Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir. Ther. 3: 215-220
9. Chaudry, N. I., Eron, J. J., Naderer, O. J., Pereira, A. S., Wire, M. B., Fiscus, S. A., Kashuba, A. D. (2002) Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin. Infect. Dis. 35: 760-762
10. Coombs, R. W., Speck, C. E., Hughes, J. P., Lee, W., Sampoleo, R., Ross, S. O., Dragavon, J., Peterson, G., Hooton, T. M., Collier, A. C., Corey, L., Koutsky, L., Krieger, J. N. (1998) Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J. Infect. Dis. 177: 320-330
11. Curran, R., Ball, J. K. (2002) Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood. J. Med. Virol. 67: 9-19
12. Daluge, S. M., Good, S. S., Faletto, M. B., Miller, W. H., St Clair, M. H., Boone, L. R., Tisdale, M., Parry, N. R., Reardon, J. E., Dornsife, R. E., Averett, D. R., Krenitsky, T. A. (1997) 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob. Agents Chemother. 41: 1082-1093
13. Dando, T. M., Perry, C. M. (2003) Enfuvirtide. Drugs 63: 2755-2766; discussion 2767-2768
14. de Ronde, A., van Dooren, M., van Der Hoek, L., Bouwhuis, D., de Rooij, E., van Gemen, B., de Boer, R., Goudsmit, J. (2001) Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75: 595-602
15. de Sousa, G., Florence, N., Valles, B., Coassolo, P., Rahmani, R. (1995) Relationships between in vitro and in vivo biotransformation of drugs in humans and animals: pharmaco-toxicological consequences. Cell Biol. Toxicol. 11: 147-153
16. Delwart, E. L., Mullins, J. I., Gupta, P., Learn, G. H. Jr, Holodniy, M., Katzenstein, D., Walker, B. D., Singh, M. K. (1998) Human immunodeficiency virus type 1 populations in blood and semen. J. Virol. 72: 617-623
17. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., Hunter, E. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74: 8358-8367
18. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., Hunter, E. (2001) Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75: 8605-8614
19. Droste, J. A., Aarnoutse, R. E., Koopmans, P. P., Hekster, Y. A., Burger, D. M. (2003) Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J. Acquir. Immune Defic. Syndr. 32: 287-291
20. Drusano, G., Preston, S., Piliero, P. (2002) Pharmacodynamics of antivirals. In: Nightingale, C. H., Murakawa, T., Ambrose, T. M. P. (eds) Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker Inc. New York, p. 259
21. Eron, J. J., Vernazza, P. L., Johnston, D. M., Seillier-Moiseiwitsch, F., Alcorn, T. M., Fiscus, S. A., Cohen, M. S. (1998) Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 12: F181-F189
22. Eron, J. J. Jr, Smeaton, L. M., Fiscus, S. A., Gulick, R. M., Currier, J. S., Lennox, J. L., D'Aquila, R. T., Rogers, M. D., Tung, R., Murphy, R. L. (2000) The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J. Infect. Dis. 181: 1622-1628
23. Fiore, J. R., Zhang, Y. J., Bjorndal, A., Di Stefano, M., Angarano, G., Pastore, G., Fenyo, E. M. (1997) Biological correlates of HIV-1 heterosexual transmission. AIDS 11: 1089-1094
24. Foster, R. H., Faulds, D. (1998) Abacavir. Drugs 55: 729-736; discussion 737-738
25. Gatti, G., Bonora, G., Liuzzi, G. (2001) ddI concentrations in seminal plasma. 8th European Conference on Clinical Aspects and Treatments of HIV-Infection, Athens
26. Ghosn, J., Chaix, M. L., Peytavin, G., Rey, E., Bresson, J. L., Goujard, C., Katlama, C., Viard, J. P., Treluyer, J. M., Rouzioux, C. (2004a) Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18: 1958-1961
27. Ghosn, J., Viard, J. P., Katlama, C., de Almeida, M., Tubiana, R., Letourneur, F., Aaron, L., Goujard, C., Salmon, D., Leruez-Ville, M., Rouzioux, C., Chaix, M. L. (2004b) Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 18: 447-457
28. Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P., Kahn, J. O. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-188
29. Gupta, P., Leroux, C., Patterson, B. K., Kingsley, L., Rinaldo, C., Ding, M., Chen, Y., Kulka, K., Buchanan, W., McKeon, B., Montelaro, R. (2000) Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen. J. Infect. Dis. 182: 79-87
30. Henry, K., Chinnock, B. J., Quinn, R. P., Fletcher, C. V., de Miranda, P., Balfour, H. H. Jr (1988) Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 259: 3023-3026
31. Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S. E., White, D. J., Drake, S. M., Khoo, S., Back, D. J. (2004) Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J. Antimicrob. Chemother. 54: 498-502
32. Kalichman, S. C., Cage, M., Barnett, T., Tharnish, P., Rompa, D., Austin, J., Luke, W., O'Mowrey, J., Schinazi, R. F. (2001) Human immunodeficiency virus in semen and plasma: investigation of sexual transmission risk behavioral correlates. AIDS Res. Hum. Retroviruses 17: 1695-1703
33. Kashuba, A. D., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J., Cohen, M. S. (1999) Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43: 1817-1826
34. Kroodsma, K. L., Kozal, M. J., Hamed, K. A., Winters, M. A., Merigan, T. C. (1994) Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J. Infect. Dis. 170: 1292-1295
35. Lafeuillade, A., Solas, C., Halfon, P., Chadapaud, S., Hittinger, G., Lacarelle, B. (2002) Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin. Trials 3: 27-35
36. Lafeuillade, A., Solas, C., Chadapaud, S., Hittinger, G., Poggi, C., Lacarelle, B. (2003) HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J. Acquir. Immune Defic. Syndr. 32: 462-464
37. Lanzendorf, S. E., Gliessman, P. M., Archibong, A. E., Alexander, M., Wolf, D. P. (1990) Collection and quality of rhesus monkey semen. Mol. Reprod. Dev. 25: 61-66
38. Law, M. G., Prestage, G., Grulich, A., Van de Ven, P., Kippax, S. (2001) Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 15: 1287-1294
39. Lawless, M. K., Hopkins, S., Anwer, M. K. (1998) Quantitation of a 36-amino-acid peptide inhibitor of HIV-1 membrane fusion in animal and human plasma using high-performance liquid chromatography and fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 707: 213-217
40. Le Tiec, C., Barrail, A., Goujard, C., Taburet, A. M. (2005) Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44: 1035-1050
41. Lewis, R. W., Kim, J. C., Irani, D., Roberts, J. A. (1981) The prostate of the nonhuman primate: normal anatomy and pathology. Prostate 2: 51-70
42. Liuzzi, G., D'Offizi, G., Topino, S., Zaccarelli, M., Amendola, A., Capobianchi, M. R., Perno, C. F., Narciso, P., Antinori, A. (2003) Dynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy. AIDS 17: 1089-1092
43. Lowe, S. H., Sankatsing, S. U., Repping, S., Veen, F. V., Reiss, P., Lange, J. M., Prins, J. M. (2004) Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS 18: 1353-1362
44. Mann, T., Lutwak-Mann, C. (1982) Passage of chemicals into human and animal semen: mechanisms and significance. Crit. Rev. Toxicol. 11: 1-14
45. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., Buclin, T. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15: 71-75
46. Mayer, K. H., Boswell, S., Goldstein, R., Lo, W., Xu, C., Tucker, L., DePasquale, M. P., D'Aquila, R., Anderson, D. J. (1999) Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin. Infect. Dis. 28: 1252-1259
47. Merigan, T. C. (1998) Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. J. Reprod. Immunol. 41: 177-185
48. Milman, G., Sharma, O. (1994) Mechanisms of HIV/SIV mucosal transmission. AIDS Res. Hum. Retroviruses 10: 1305-1312
49. Molla, A., Vasavanonda, S., Kumar, G., Sham, H. L., Johnson, M., Grabowski, B., Denissen, J. F., Kohlbrenner, W., Plattner, J. J., Leonard, J. M., Norbeck, D. W., Kempf, D. J. (1998) Human serum attenuates the activity of protease inhibitors toward wildtype and mutant human immunodeficiency virus. Virology 250: 255-262
50. Montaner, J., Hill, A., Acosta, E. (2001) Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 357: 1438-1440
51. Musicco, M., Lazzarin, A., Nicolosi, A., Gasparini, M., Costigliola, P., Arici, C., Saracco, A. (1994) Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch. Intern. Med. 154: 1971-1976
52. Nicolosi, A., Musicco, M., Saracco, A., Lazzarin, A. (1994a) Risk factors for woman-to-man sexual transmission of the human immunodeficiency virus. Italian Study Group on HIV Heterosexual Transmission. J. Acquir. Immune Defic. Syndr. 7: 296-300
53. Nicolosi, A., Correa Leite, M. L., Musicco, M., Arici, C., Gavazzeni, G., Lazzarin, A. (1994b) The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 5: 570-575
54. O'Brien, T. R., Busch, M. P., Donegan, E., Ward, J. W., Wong, L., Samson, S. M., Perkins, H. A., Altman, R., Stoneburner, R. L., Holmberg, S. D. (1994) Heterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners. J. Acquir. Immune Defic. Syndr. 7: 705-710
55. Pereira, A. S., Kashuba, A. D., Fiscus, S. A., Hall, J. E., Tidwell, R. R., Troiani, L., Dunn, J. A., Eron, J. J. Jr, Cohen, M. S. (1999) Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J. Infect. Dis. 180: 2039-2043
56. Pereira, A. S., Kenney, K. B., Cohen, M. S., Hall, J. E., Eron, J. J., Tidwell, R. R., Dunn, J. A. (2000) Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 742: 173-183
57. Pereira, A. S., Smeaton, L. M., Gerber, J. G., Acosta, E. P., Snyder, S., Fiscus, S. A., Tidwell, R. R., Gulick, R. M., Murphy, R. L., Eron, J. J. Jr (2002) The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J. Infect. Dis. 186: 198-204
58. Pichini, S., Zuccaro, P., Pacifici, R. (1994) Drugs in semen. Clin. Pharmacokinet. 26: 356-373
59. Reddy, Y. S., Gotzkowsky, S. K., Eron, J. J., Kim, J. Y., Fiske, W. D., Fiscus, S. A., Petch, L., Cohen, M. S., Kashuba, A. D. (2002) Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J. Infect. Dis. 186: 1339-1343
60. Reddy, Y. S., Kashuba, A., Gerber, J., Miller, V. (2003) Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res. Hum. Retroviruses 19: 167-176
61. Renkin, E., Crone, C. (1996) Microcirculation and capillary exchange. In: Greger, R., Windhorst, U. (eds) Comprehensive human physiology. Springer-Verlag, Berlin, pp 1965-1979
62. Sadler, B. M., Gillotin, C., Lou, Y., Stein, D. S. (2001) Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45: 30-37
63. Sankatsing, S. U., Droste, J., Burger, D., Van Praag, R. M., Jurriaans, S., Lange, J. M., Prins, J. M. (2002) Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS 16: 1698-700
64. Shah, V. P., Midha, K. K., Findlay, J. W., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tonelli, A., Viswanathan, C. T., Yacobi, A. (2000) Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17: 1551-1557
65. Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger, G., Lacarelle, B. (2003) Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47: 238-243
66. Sparidans, R., Hoetelmans, R. M., Beijnen, J. (2000) Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen. J. Chromatogr. B 742: 185-192
67. Taylor, P. J. (2005) Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38: 328-334
68. Taylor, S., Pereira, A. (2000) Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med. 1 (Suppl. 2): 18-22
69. Taylor, S., Pereira, A. S. (2001) Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex. Transm. Infect. 77: 4-11
70. Taylor, S., Back, D. J., Workman, J., Drake, S. M., White, D. J., Choudhury, B., Cane, P. A., Beards, G. M., Halifax, K., Pillay, D. (1999) Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 13: 859-860
71. Taylor, S., van Heeswijk, R. P., Hoetelmans, R. M., Workman, J., Drake, S. M., White, D. J., Pillay, D. (2000) Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 14: 1979-1984
72. Taylor, S., Reynolds, H., Sabin, C. A. (2001a) Penetration of non-nucleoside reverse transcriptase inhibitors (NNRTIs) into the male genital tract: variable drug concentrations in semen and blood plasma of HIV-1 infected men. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk
73. Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., White, D. J., Pillay, D. (2001b) Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J. Antimicrob. Chemother. 48: 351-354
74. Taylor, S., Reynolds, H., Sabin, C. A. (2001c) Penetration of non-nucleoside reverse transcriptase inhibitors (NNRTIs) into the male genital tract: variable drug concentrations in semen and blood plasma of HIV-I infected men. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk
75. Taylor, S., Boffito, M., Vernazza, P. L. (2003a) Antiretroviral therapy to reduce the sexual transmission of HIV. J. HIV Ther. 8: 55-66
76. Taylor, S., Sadiq, S. T., Weller, I., Kaye, S., Workman, J., Cane, P. A., Bennett, J., Copas, A. J., Drake, S. M., Pillay, D. (2003b) Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Antivir. Ther. 8: 479-483
77. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 322: 1087-1088
78. US Department of Health and Human Services (1998) Guidance for industry. Bioanalytical methods validation for human studies. Food and Drug Administration, UdoHaHS, Drug Information Branch (CDER), Rockville, MD
79. US Food and Drug Administration, Center for Drug Evaluation and Research (2004) NDA 21-752. Available at: http://www.fda.gov/cder/foi/label/2004/ 217521bl.pdf
80. US National Institutes of Health (2006) Preventing sexual transmission of HIV with anti-HIV drugs. Available at: http://clinicaltrials.gov/ct/ show/NCT00074581;jsessionid=3A29CECBF9B73115711C0A951CA75855?order=1
81. van Leeuwen, E., ter Heine, R., van der Veen, F., Repping, S., Beijnen, J. H., Prins, J. M. (2007) Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51: 335-337
82. van Praag, R. M., Weverling, G. J., Portegies, P., Jurriaans, S., Zhou, X. J., Turner-Foisy, M. L., Sommadossi, J. P., Burger, D. M., Lange, J. M., Hoetelmans, R. M., Prins, J. M. (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 14: 1187-1194
83. van Praag, R. M., Repping, S., de Vries, J. W., Lange, J. M., Hoetelmans, R. M., Prins, J. M. (2001a) Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob. Agents Chemother. 45: 2902-2907
84. van Praag, R. M., van Heeswijk, R. P., Jurriaans, S., Lange, J. M., Hoetelmans, R. M., Prins, J. M. (2001b) Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin. Infect. Dis. 33: e91-92
85. Vernazza, P. L., Eron, J. J., Cohen, M. S., van der Horst, C. M., Troiani, L., Fiscus, S. A. (1994) Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 8: 1325-1329
86. Vernazza, P. L., Eron, J. J., Fiscus, S. A. (1996) Sensitive method for the detection of infectious HIV in semen of seropositive individuals. J. Virol. Methods 56: 33-40
87. Vernazza, P. L., Gilliam, B. L., Dyer, J., Fiscus, S. A., Eron, J. J., Frank, A. C., Cohen, M. S. (1997a) Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 11: 987-993
88. Vernazza, P. L., Gilliam, B. L., Flepp, M., Dyer, J. R., Frank, A. C., Fiscus. S. A., Cohen, M. S., Eron, J. J. (1997b) Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 11: 1249-1254
89. Vernazza, P. L., Troiani, L., Flepp, M. J., Cone, R. W., Schock, J., Roth, F., Boggian, K., Cohen, M. S., Fiscus, S. A., Eron, J. J. (2000) Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 14: 117-121
90. Wainberg, M. A., Beaulieu, R., Tsoukas, C., Thomas, R. (1993) Detection of zidovudine-resistant variants of HIV-1 in genital fluids. AIDS 7: 433-434
91. Wang, S., Cyronak, M., Yang, E. (2007) Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma. J. Pharm. Biomed. Anal. 43: 701-707
92. Yerly, S., Kaiser, L., Race, E., Bru, J. P., Clavel, F., Perrin, L. (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354: 729-733
93. Yu, L., Bridgers, A., Polli, J., Vickers, A., Long, S., Roy, A., Winnike, R., Coffin, M. (1999) Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16: 1812-1817
94. Zhu, T., Wang, N., Carr, A., Nam, D. S., Moor-Jankowski, R., Cooper, D. A., Ho, D. D. (1996) Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70: 3098-3107